TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

F. Demichelis, K. Fall, S. Perner, O. Andrén, F. Schmidt, S. R. Setlur, Y. Hoshida, J. M. Mosquera, Y. Pawitan, C. Lee, H. O. Adami, L. A. Mucci, P. W. Kantoff, S. O. Andersson, A. M. Chinnaiyan, J. E. Johansson, M. A. Rubin

Research output: Contribution to journalArticlepeer-review

512 Scopus citations


The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high estrogen-regulated gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.

Original languageEnglish (US)
Pages (from-to)4596-4599
Number of pages4
Issue number31
StatePublished - Jul 5 2007
Externally publishedYes


  • Cancer-specific death
  • ERG
  • ETS
  • Prognosis
  • Prostate cancer

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research


Dive into the research topics of 'TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort'. Together they form a unique fingerprint.

Cite this